Characterization of the cytochrome P450 isoenzymes involved in the in vitro N-dealkylation of haloperidol

British Journal of Clinical Pharmacology

Volumn 44, Issue 6, 1997, Pages 557-564

  Pan, L P ^a   Wijnant, P ^a   De Vriendt, C ^a   Rosseel, M T ^a   Belpaire, F M ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

CYP3A4; Cytochrome P450 isoenzymes; Haloperidol; Human liver microsomes; In vitro metabolism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; FURAFYLLINE; HALOPERIDOL; QUINIDINE; REDUCED HALOPERIDOL; SULFAPHENAZOLE; TOLBUTAMIDE;

ARTICLE; DEALKYLATION; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL;

EID: 0030716846     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00629.x     Document Type: Article

References (33)

1. Tsang MW, Shader RI, Greenblatt DJ. Metabolism of haloperidol: Clinical implications and unanswered questions. J Clin Psychopharmacol 1994; 14: 159-162.
2. Soudijn W, Wijngaarden I, Allewijn F. Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Eur J Pharmacol 1967; 1: 47-57.
3. Gorrod JW, Fang J. On the metabolism of haloperidol. Xenobiotica 1993; 23: 495-508.
4. Inaba T, Kovacs J. Haloperidol reductase in human and guinea pig livers. Drug Metab Dispos 1989; 17: 330-333.
5. Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450 IID6 (sparteine/debrisoquine monooxygenase). Br J Clin Pharmacol 1991; 31: 655-660.
6. Oida T, Terauchi Y, Yoshida K, Kagemoto A, Sekine Y. Use of antisera in the isolation of human specific conjugates of haloperidol. Xenobiotica 1989; 19: 781-793.
7. + found in rat brain following IP administration of HP. Life Sci 1995; 57: 2439-2446.
8. Usuki E, Pearce R, Parkinson A, Castagnol N. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolite by human liver microsomes. Chem Res Toxicol 1996; 9: 800-806.
9. Eyles DW, McLennan HR, Jones A, McGrath JJ, Stedman TJ, Pond SM. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 1994; 56: 512-520.
10. LLerena A, Alm C, Dahl M, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92-97.
11. Young D, Midha KK, Fossler MJ, et al. Effect of quinidine on the interconversion kinetics between haloperidol and reduced haloperidol in humans: implications for the involvement of cytochrome P450IID6. Eur J Clin Pharmacol 1993; 44: 433-438.
12. Fang J, Baker GB, Silverstone PH, Coutts RT. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol 1997; 17; 227-233.
13. Inaba T, Jurima M, Mahon WA, Kalow W. In vitro inhibition of two isoenzymes of human liver cytochrome P-450: mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos 1985; 13: 443-448.
14. Gram LF, Debruyne D, Caillard V, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989; 27: 272-275.
15. Amar-Costesec A, Beaufayt H, Wibo M, et al. Analytical study of microsomes and isolated subcellular membranes from rat liver. J Cell Biol 1974; 61: 201-212.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein-dye binding. Anal Biochem 1976; 72: 248-252.
17. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6-and CYP3A4-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3: 197-204.
18. Gorski JC, Jones OR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P4503A4 (CYP3A4) subfamily. Biochem Pharmacol 1994; 48: 173-182.
19. Sesardic D, Boobis AR, Edwards RJ, Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 1988; 26: 363-372.
20. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22: 1-21.
21. Bartoletti RA, Belpaire FM, Rosseel MT. High performance liquid chromatography determination of dextromethorphan and its metabolites in urine using solid-phase extraction. J Pharm Biomed Anal 1996; 14: 1281-1286.
22. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Biochem Pharmacol 1988; 37: 1137-1144.
23. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953; 55: 170-171.
24. Jann MW, Lam YWF, Chang WH. Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacol 1990; 101: 107-111.
25. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993; 25: 453-484.
26. Guengerich FP. Characterization of human microsomal cytochrome P450 enzymes. Ann Rev Pharmacol Toxicol 1989; 29: 241-264.
27. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastrointestin Pharmacol 1992; 21: 511-526.
28. Shou M, Gropgan J, Mancewicz JA, et al. Activition of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994; 33: 6450-6455.
29. Shimada T, Yamazaki H, Inui M, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
30. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
31. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokin 1996; 31: 198-214.
32. Jann MW, Ereshefsky L, Saklad SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5: 106-109.
33. Kidron R, Averbuch I, Klein E, et al. Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia. Biol Psychiatry 1985; 20: 219-222.